FOSUN PHARMA(02196),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02196 FOSUN PHARMA

Not Yet Opened 04-08 16:08:54

13.400

+0.260

+1.98%

High13.660	Low13.060	Vol6.24M
Open13.440	D1 Closing13.140	Amplitude4.57%
Mkt Cap35.68B	Tradable Cap7.28B	Total Shares2.66B
T/O83.44M	T/O Rate1.15%	Tradable Shares543.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"02196","market":"HK","secType":"STK","nameCN":"FOSUN PHARMA","latestPrice":13.4,"timestamp":1744099734016,"preClose":13.14,"halted":0,"volume":6244416,"delay":0,"floatShares":543000000,"shares":2663000000,"eps":1.0877112524206962,"marketStatus":"Not Yet Opened","change":0.26,"latestTime":"04-08 16:08:54","open":13.44,"high":13.66,"low":13.06,"amount":83439481,"amplitude":0.045662,"askPrice":13.42,"askSize":21000,"bidPrice":13.4,"bidSize":500,"shortable":3,"etf":0,"ttmEps":1.0877112524206962,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1744162200000},"marketStatusCode":0,"adr":0,"listingDate":1351526400000,"exchange":"SEHK","adjPreClose":13.14,"dividendRate":0.025253,"openAndCloseTimeList":[[1744075800000,1744084800000],[1744088400000,1744099200000]],"volumeRatio":0.74067,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.","latestPrice":23.7,"timestamp":1744095600000,"preClose":23.2,"halted":0,"volume":25956200,"delay":0,"premium":"-46.08"}},"requestUrl":"/m/hq/s/02196/wiki","defaultTab":"wiki","newsList":[{"id":"2525830535","title":"Fosun Pharmaceutical Unit Gets China Nod for Schizophrenia Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2525830535","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525830535?lang=en_us&edition=full_marsco","pubTime":"2025-04-08 15:00","pubTimestamp":1744095612,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical   unit Fosun Pharma  received clinical trial approval for its CMC-2310 Oral Soluble Film from China's National Medical Products Administration.The clinical trial will test the drug for the treatment of schizophrenia in adults and pediatric patients aged 13 and above, a Monday filing with the Hong Kong bourse said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","BK1191","BK1593","BK0188","BK0175","BK0196","BK0096","600196","00656","BK0012","BK0060","BK0028","BK1230","BK1515","BK0183","02196","BK0187"],"gpt_icon":0},{"id":"2524137478","title":"Shanghai Fosun Pharmaceutical Raises Stake in United Health Insurance; Shares Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2524137478","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524137478?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 13:46","pubTimestamp":1743486361,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical Raises Stake in United Health Insurance; Shares RiseShanghai Fosun Pharmaceutical   signed a Share Subscription Agreement with IFC and ADB to invest 270 million yuan each in United Health Insurance, according to a Monday filing with the Hong Kong bourse.The deal will increase Fosun Pharma's stake in the insurer from 14.00% to 20.05%. The capital infusion, totaling 810 million yuan, will support the company's expansion. The transaction does not require the approval of independent shareholders.Fosun Pharma views this investment as a strategic move to enhance its presence in China's rapidly growing health insurance sector.The pharmaceuticals shares were up 6% in Hong Kong and 4% in Shanghai in recent trading.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4211","BK0196","BK1230","600196","BK0096","BK1191","BK0183","BK0012","BK0060","BK0175","BK0028","02196","BK1515","BK1593","BK0188","BK0187","00656","BK0239","UBCP"],"gpt_icon":0},{"id":"2522998528","title":"Fosun Pharmaceutical-Owned Gland Pharma to Invest 1.6 Billion Yuan in Indian Mutual Funds, Bonds","url":"https://stock-news.laohu8.com/highlight/detail?id=2522998528","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522998528?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 13:25","pubTimestamp":1742966702,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical  subsidiary Gland Pharma  is planning to invest up to 20 billion Indian rupees  in Indian mutual funds and government or corporate bonds.Investments will be in low-risk mutual funds and bond products in accordance with the principle of strict risk control, according to a Tuesday filing with the Shanghai bourse.The authorization is valid until March 31, 2027.Fosun Pharma's shares fell nearly 2% in Hong Kong and almost 1% in Shanghai recently.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0012","BK1515","BK0096","BK1191","02196","BK0183","BK0239","BK1230","BK0028","BK0175","BK1593","BK0187","BK0060","BK0196","00656","600196","BK0188"],"gpt_icon":0},{"id":"2522955468","title":"China's NAFMII Accepts Fosun Pharma's Application to Issue Up to 10 Billion Yuan Bonds","url":"https://stock-news.laohu8.com/highlight/detail?id=2522955468","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522955468?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 12:56","pubTimestamp":1742964971,"startTime":"0","endTime":"0","summary":"China's National Association of Financial Market Institutional Investors accepted the application of Shanghai Fosun Pharmaceutical   to issue bonds of up to 10 billion yuan, according to a Hong Kong Stock Exchange filing on Tuesday.The bonds are medium-term bonds worth 4 billion yuan and super short-term bonds amounting to 6 billion yuan.The issuance of both bonds is valid within two years. Bank of Shanghai  and China Merchants Bank  will serve as the joint lead underwriters for the issuances, the pharmaceutical company said.The company's Hong Kong shares fell less than 2% in recent trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2778985437.USD","LU0821914370.USD","LU1224709979.USD","LU1997244956.HKD","LU1008478684.HKD","LU2097828474.EUR","BK0096","LU2097828805.USD","BK0015","BK0020","BK0060","LU0315179316.USD","LU0348788117.USD","600196","600036","LU1211504680.USD","601229","IE00B543WZ88.USD","LU1820825898.SGD","00656","IE00B031HY20.USD","BK0196","03143","BK0175","LU1969619763.USD","03968","IE00BZ08YS42.EUR","LU0163747925.USD","IE00B5MMRT66.SGD","LU0823426480.USD","LU1242518857.USD","LU0384037296.USD","02196","LU0067412154.USD","LU1226287529.USD","LU0320764243.SGD","LU1282649141.HKD","BK0278","LU1997245177.USD","LU2242644610.SGD","LU0314109678.HKD","BK1521","BK1560","LU0173614495.USD","LU2097828714.EUR","BK0070","LU1064130708.USD","LU0648948544.HKD","LU2148510915.USD","BK0010"],"gpt_icon":0},{"id":"2522386319","title":"Press Release: Fosun Pharma Announces 2024 Annual Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2522386319","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522386319?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 10:29","pubTimestamp":1742956140,"startTime":"0","endTime":"0","summary":"Accelerates Globalization of Innovative Products with Operating Cash Flow Surging 31.13% YoY. SHANGHAI, March 25, 2025 /PRNewswire/ -- On March 25, 2025, Shanghai Fosun Pharmaceutical  Co., Ltd. , a leading global pharmaceutical and healthcare company driven by innovation, announced its annual results for the year ended 31 December 2024 .During the Reporting Period, Fosun Pharma continuously optimized its innovative R&D system while maintaining stable R&D investment, focusing on key pipeline strengths and enhancing efficiency through system integration. In 2024, Fosun Pharma's total R&D expenditure amounted to RMB5.55 billion, with R&D expenses totaling RMB3.64 billion. The R&D expenditure in the pharmaceutical manufacturing segment amounted to RMB4.91 billion, accounting for 16.98% of pharmaceutical business revenue. There are over 80 major pipeline projects on innovative drugs and biosimilars . In addition, during the Reporting Period, the pharmaceutical manufacturing segment of Fosu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0060","BK1230","BK0175","02196","BK0028","PN","BK1191","BK0012","00656","BK1515","600196","BK0183","BK1593","BK0096","BK0187","BK4096","BK0196","BK0239","BK0188"],"gpt_icon":0},{"id":"2519828447","title":"Shanghai Fosun Pharmaceutical (Group)'s Subsidiary PNH Drug Gets NMPA's Nod for Clinical Trials; Shares Rise 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2519828447","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519828447?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 15:57","pubTimestamp":1741939046,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical 's  subsidiary S-INFINITY Pharmaceuticals received approval from China's National Medical Products Administration  for the clinical trial Phase II of XH-S003 capsules, according to a Thursday filing with the Hong Kong bourse.XH-S003 is a small molecule inhibitor of the complement system to treat paroxysmal nocturnal hemoglobinuria .The Pharmaceutical's shares were up by 4% in recent trading.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02196","BK0175","BK0012","BK0028","BK0196","BK1191","BK0060","BK0239","BK0096","BK0183","BK0187","BK0188","600196","BK1593","00656","BK1515"],"gpt_icon":1},{"id":"2519819261","title":"Fosun Pharma Gets Clinical Trial Approval for Blood Disorder Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2519819261","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519819261?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 11:08","pubTimestamp":1741921701,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical  subsidiary Xinghao Pengbo received approval from China's drug administrator to conduct phase two clinical trials for XH-S003 capsule.The drug targets paroxysmal nocturnal hemoglobinuria, a rare blood disorder, according to a Wednesday filing with the Shanghai bourse.Shares of the pharmaceutical company rose 1% in recent trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0196","BK0175","BK0187","BK0096","600196","BK0060","BK1191","BK0183","BK0188","BK1515","BK1593","00656","BK0028","BK0239","02196","BK0012"],"gpt_icon":0},{"id":"2517126956","title":"Fosun Pharma Unit Gets China Nod to Register Foritinib Succinate Capsules","url":"https://stock-news.laohu8.com/highlight/detail?id=2517126956","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517126956?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 12:42","pubTimestamp":1741322561,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical's  unit, Fosun Wanbang  Pharmaceutical Group, has secured approval from China's National Medical Products Administration to register its foritinib succinate capsules, according to a Hong Kong stock exchange filing on Thursday.The drug is primarily used to treat non-small cell lung cancer patients that are anaplastic lymphoma kinase-positive and those with non-small cell lung cancer , the pharmaceutical company said.Shares of Fosun Pharma rose over 2% in Hong Kong and nearly 1% in Shanghai in recent trading.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0196","BK0183","600196","BK0187","02196","BK0096","BK0239","BK1515","00656","BK0060","BK1230","BK0188","BK0175","BK0028","BK0012","BK1593","BK1191"],"gpt_icon":0},{"id":"2516768536","title":"Chinese Regulator Approves Shanghai Fosun Pharmaceutical's Vaccine for Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2516768536","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516768536?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 21:07","pubTimestamp":1741093665,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical's   subsidiary Fosun Adgenvax  Biopharmaceutical obtained the National Medical Products Administration's approval for clinical trials for its 24-valent pneumococcal polysaccharide conjugate vaccine, a Tuesday bourse filing said.Fosun Adgenvax  Biopharmaceutical plans to start the first phase of clinical trials in China.The vaccine is a preventive biological product used for the prevention of certain infectious diseases caused by certain pneumococcal serotypes.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1593","BK0188","BK0175","BK0187","00656","BK0196","BK0239","BK0096","BK0028","BK1515","BK0012","600196","BK1191","BK0060","02196","BK0183"],"gpt_icon":0},{"id":"2514434848","title":"Fosun Pharmaceutical Gets Marketing Authorization for Chronic Kidney Disease Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2514434848","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514434848?lang=en_us&edition=full_marsco","pubTime":"2025-02-27 11:58","pubTimestamp":1740628689,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical  obtained marketing authorization for tenapanol hydrochloride tablets from China's food and drug administrator.The drug is used to control serum phosphorus levels in adult dialysis patients with chronic kidney disease who have inadequate response or intolerance to phosphate binders, according to a Thursday filing with the Shanghai bourse.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0012","BK1515","BK0096","BK1191","02196","BK0183","BK0239","BK0028","BK0175","BK1593","BK0187","BK0060","BK0196","00656","600196","BK0188"],"gpt_icon":0},{"id":"2514319348","title":"Fosun Pharmaceutical Unit Gets Chinese Regulator's Nod for Chronic Kidney Disease Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=2514319348","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514319348?lang=en_us&edition=full_marsco","pubTime":"2025-02-26 20:21","pubTimestamp":1740572493,"startTime":"0","endTime":"0","summary":"China approved Shanghai Fosun Pharmaceutical  subsidiary Shanghai Fosun Pharmaceutical Industrial Development's tenapanor hydrochloride tablets for an indication of chronic kidney disease, according to a Wednesday filing with the Hong Kong Exchange.The tablets help control serum phosphorus levels in dialysis patients with chronic kidney disease who do not have an adequate response to phosphorus binders, the filing said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0175","600196","BK0183","BK1191","BK0187","BK0060","BK0096","BK1593","02196","BK0188","BK0196","00656","BK1515","BK0012","BK0028","BK0239"],"gpt_icon":0},{"id":"2514675831","title":"Fosun Pharmaceutical Unit Gets China Nod for Lung Diseases Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2514675831","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514675831?lang=en_us&edition=full_marsco","pubTime":"2025-02-26 20:18","pubTimestamp":1740572317,"startTime":"0","endTime":"0","summary":"China accepted Shanghai Fosun Pharmaceutical  subsidiary Yaopharma's drug registration application for its bromhexine hydrochloride injection, according to a Wednesday filing with the Hong Kong Exchange.The drug is an expectorant indicated for lung ailments such as pulmonary tuberculosis, pneumoconiosis, or postoperative sputum retention, the filing said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1515","BK0183","00656","BK0028","BK0196","02196","BK0060","BK0188","BK1593","BK0187","BK0239","BK1191","BK0096","BK0175","BK0012","600196"],"gpt_icon":0},{"id":"2514315528","title":"Fosun Pharmaceutical Unit Gets China Nod for Colon Cleansing Granules","url":"https://stock-news.laohu8.com/highlight/detail?id=2514315528","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514315528?lang=en_us&edition=full_marsco","pubTime":"2025-02-26 20:17","pubTimestamp":1740572245,"startTime":"0","endTime":"0","summary":"China granted Shanghai Fosun Pharmaceutical  subsidiary Suzhou Erye Pharmaceutical marketing approval for its compound sodium picosulfate granules for colon cleansing.The drug contains sodium picosulfate, magnesium oxide, and anhydrous citric acid, and is used to clean the colon for colonoscopy or X-rays, and for preparation for colon surgery, according to a Wednesday filing with the Hong Kong Exchange.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0188","BK0096","600196","BK1515","BK0183","00656","BK1593","02196","BK0187","BK0239","BK0196","BK0060","BK0012","BK1191","BK0175","BK0028"],"gpt_icon":0},{"id":"2514898880","title":"BRIEF-Shanghai Fosun Pharma's Unit Received Marketing Registration Approval From NMPA China For Compound Sodium Picosulfate Granules","url":"https://stock-news.laohu8.com/highlight/detail?id=2514898880","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514898880?lang=en_us&edition=full_marsco","pubTime":"2025-02-26 18:31","pubTimestamp":1740565889,"startTime":"0","endTime":"0","summary":"BRIEF-Shanghai Fosun Pharma's Unit Received Marketing Registration Approval From NMPA China For Compound Sodium Picosulfate GranulesFeb 26  - Shanghai Fosun Pharmaceutical Group Co Ltd 600196.SS:UNIT RECEIVED MARKETING REGISTRATION APPROVAL FROM NMPA CHINA FOR COMPOUND SODIUM PICOSULFATE GRANULESFurther company coverage: 600196.SS ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nFWN3PH0XP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK0060","02196","BK0183","BK0187","BK0188","BK0175","BK1191","BK0028","BK1593","600196","BK0239","BK0012","BK0096","BK0196"],"gpt_icon":0},{"id":"2513730498","title":"BRIEF-Anhui Sunhere Says Shareholder Shanghai Fosun Pharma To Unload Up To 3% Stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2513730498","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513730498?lang=en_us&edition=full_marsco","pubTime":"2025-02-23 21:31","pubTimestamp":1740317465,"startTime":"0","endTime":"0","summary":"BRIEF-Anhui Sunhere Says Shareholder Shanghai Fosun Pharma To Unload Up To 3% Stake Feb 23  - Anhui Sunhere 300452.SZ:SAYS SHAREHOLDER SHANGHAI FOSUN PHARMACEUTICAL PLANS TO UNLOAD UP TO 3% STAKE IN THREE MONTHSSource textFurther company coverage: 300452.SZ  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250223:nL3N3PE02D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0175","600196","BK0183","BK1191","BK0177","BK0187","BK0060","BK0096","BK1593","02196","BK0188","BK0196","300452","BK1515","BK0012","BK0028","BK0239"],"gpt_icon":0},{"id":"2513304677","title":"Anhui Sunhere  Says Shareholder Shanghai Fosun Pharmaceutical Plans to Unload up to 3% Stake in Three Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2513304677","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513304677?lang=en_us&edition=full_marsco","pubTime":"2025-02-23 21:31","pubTimestamp":1740317465,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250223:nL3N3PE02D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0196","BK0183","600196","BK0187","02196","BK0096","300452","BK0239","BK1515","BK0060","BK0188","BK0175","BK0177","BK0028","BK0012","BK1593","BK1191"],"gpt_icon":0},{"id":"2513256688","title":"Fosun Pharma Unit to Boost Stake in Medical Services Firm with Additional Investment","url":"https://stock-news.laohu8.com/highlight/detail?id=2513256688","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513256688?lang=en_us&edition=full_marsco","pubTime":"2025-02-21 16:23","pubTimestamp":1740126196,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical  unit Shanghai Fosun Health Technology will inject 30 million yuan into Shanghai Zhuoerhui Integrated Outpatient.The capital contribution will mainly be to support the target company's daily operations and the construction of its disciplines, branding, and marketing system.Following completion, Fosun Health's shareholding in the target will rise to 67.1872% from 57.5363%, a Thursday filing with the Hong Kong bourse said.Shanghai Zhuoerhui Integrated Outpatient mainly provides medical services such as physical examination and general and specialist outpatient clinics.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1230","00656","BK1515","02196","BK0096","600196","BK0175","BK0183","BK0196","BK1593","BK0060","BK0188","BK0187","BK0239","BK1191","BK0012","BK0028"],"gpt_icon":0},{"id":"2510540847","title":"Fosun Pharmaceutical Gets US FDA Approval for HLX99 Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2510540847","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510540847?lang=en_us&edition=full_marsco","pubTime":"2025-02-11 11:07","pubTimestamp":1739243224,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical  received approval from the US Food and Drug Administration to conduct phase one clinical trials for HLX99.The drug is used for the treatment of amyotrophic lateral sclerosis, according to a Monday filing with the Shanghai bourse.Shares of the pharmaceutical company were down 1% in recent trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0188","BK0028","600196","BK0175","BK1593","BK0060","BK1515","BK0012","BK1191","BK0196","BK0096","00656","BK0183","02196","BK0239","BK0187"],"gpt_icon":0},{"id":"2510520418","title":"Chinese regulator Accepts New Drug Applications from Shanghai Fosun Pharmaceutical's Two Subsidiaries","url":"https://stock-news.laohu8.com/highlight/detail?id=2510520418","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510520418?lang=en_us&edition=full_marsco","pubTime":"2025-02-10 21:36","pubTimestamp":1739194567,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196) said the National Medical Products Administration accepted drug registration applications for two drugs developed by two of its subsidiaries, a Mon","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0012","BK0187","BK1230","00656","BK0060","BK0175","BK0028","02196","BK1515","BK0239","600196","BK1593","BK0096","BK1191","BK0188","BK0183","BK0196"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fosunpharma.com","stockEarnings":[{"period":"1week","weight":-0.1487},{"period":"1month","weight":-0.1366},{"period":"3month","weight":-0.0045},{"period":"6month","weight":-0.1253},{"period":"1year","weight":0.1334},{"period":"ytd","weight":-0.051}],"compareEarnings":[{"period":"1week","weight":-0.1327},{"period":"1month","weight":-0.1694},{"period":"3month","weight":0.044},{"period":"6month","weight":-0.0529},{"period":"1year","weight":0.2029},{"period":"ytd","weight":0.0034}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Shanghai Fosun Pharmaceutical Group Co Ltd is a China-based company mainly engaged in the research and development, manufacturing and sales of pharmaceutical products. The Company operates in five segments. Pharmaceutical segment is mainly engaged in the manufacturing of innovative drugs, mature pharmaceutical products and vaccines. Medical Devices and Medical Diagnostics segment is mainly engaged in the manufacturing and sales of medical cosmetic devices such as molecular diagnosis, immunodiagnosis, and microbial diagnosis. Medical Health Services segment is mainly engaged in the operation of an online and offline integrated medical service platform. Pharmaceutical Distribution and Retail segment is mainly engaged in the wholesale and retail of pharmaceutical products. Others segment is engaged in other pharmaceutical-related businesses. The Company's products are mainly used in the treatment of tumors, immunity, central nervous system and other fields.","yearOnYearQuotes":[{"month":1,"riseRate":0.384615,"avgChangeRate":-0.051329},{"month":2,"riseRate":0.769231,"avgChangeRate":0.040456},{"month":3,"riseRate":0.615385,"avgChangeRate":0.048425},{"month":4,"riseRate":0.384615,"avgChangeRate":0.027778},{"month":5,"riseRate":0.416667,"avgChangeRate":0.023533},{"month":6,"riseRate":0.416667,"avgChangeRate":-0.030975},{"month":7,"riseRate":0.583333,"avgChangeRate":0.016784},{"month":8,"riseRate":0.25,"avgChangeRate":-0.056335},{"month":9,"riseRate":0.416667,"avgChangeRate":-0.002919},{"month":10,"riseRate":0.5,"avgChangeRate":0.028409},{"month":11,"riseRate":0.461538,"avgChangeRate":0.046301},{"month":12,"riseRate":0.461538,"avgChangeRate":0.021537}],"exchange":"SEHK","name":"FOSUN PHARMA","nameEN":"FOSUN PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"FOSUN PHARMA(02196),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest FOSUN PHARMA(02196) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"FOSUN PHARMA,02196,FOSUN PHARMA股票,FOSUN PHARMA股票老虎,FOSUN PHARMA股票老虎国际,FOSUN PHARMA行情,FOSUN PHARMA股票行情,FOSUN PHARMA股价,FOSUN PHARMA股市,FOSUN PHARMA股票价格,FOSUN PHARMA股票交易,FOSUN PHARMA股票购买,FOSUN PHARMA股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"FOSUN PHARMA(02196),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest FOSUN PHARMA(02196) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}